Ge Healthcare

European Federation of the Neurological Societies Cites Utility of DaTSCAN in Differentiating Alzheimer's Disease from Dementia with Lewy Bodies

Iobenguane I 123 Injection Studied for Its Ability to Identify Risk in Patients with Symptomatic Heart Failure (HF)

GE Healthcare Presents Positive Phase 2 Data with Flutemetamol - Phase 3 Program Now Underway

PRINCETON, New Jersey, October 14, 2010 - GE Healthcare, a unit of General Electric Company (NYSE: GE), today announced that DaTSCAN(TM) (ioflupane I 123 injection), a radiopharmaceutical agent intended for use with single photon emission computed tomography (SPECT) imaging of the brain, has been recommended in updated European Federation of the Neurological Societies (EFNS) guidelines for the diagnosis and management of Alzheimer's disease (AD).

MORE..

PRINCETON, New Jersey, May 17, 2010 - The ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) trial, the results of which were published in the May 18th, 2010 issue of the Journal of the American College of Cardiology, is a prospective study evaluating cardiac sympathetic nerve imaging using Iobenguane I 123 Injection (AdreView(TM)) for identifying symptomatic heart failure patients most likely to experience cardiac events.

MORE..

Older News

TORONTO, April 9, 2010 - GE Healthcare will today present results from its multicenter phase 2 study of flutemetamol at the 4th annual Human Amyloid Imaging (HAI) Meeting in Toronto, Canada.

MORE..